EPAS1 and nonpapillary renal cell carcinoma: Furthermore, the relationship between Hippo pathway alterations and major drivers of ccRCC development (such as VHL, SETD2, and BAP2 mutations as well as HIF1 and HIF2α activation) is not currently clear.